4.5 Article

Costs Associated With Treatment of Chronic Low Back Pain An Analysis of the UK General Practice Research Database

期刊

SPINE
卷 38, 期 1, 页码 75-82

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BRS.0b013e318276450f

关键词

chronic lower back pain; cost; burden; General Practice Research Database; United Kingdom

资金

  1. Eli Lilly and Company funds

向作者/读者索取更多资源

Study Design. Retrospective cohort study of health care costs associated with the treatment of chronic low back pain (CLBP) in the United Kingdom. Objective. To assess 12-month health care costs associated with the treatment of CLBP, using the UK General Practice Research Database. Summary of Background Data. CLBP is a common health problem. Methods. Data were obtained from the General Practice Research Database, a computerized database of UK primary care patient data. Patients with CLBP were identified for the study period (January 1, 2007, to December 31, 2009) using diagnostic records and pain relief prescriptions (n = 64,167), and 1:1 matched to patients without CLBP (n = 52,986) on the basis of age, sex, and general practitioner's practice. Index date was defined as the first date of CLBP record; the same index date was assigned to matched controls. Multivariate analyses were performed to compare resource use costs (2009 values) in the 12 months after the index date between patients with and without CLBP. A sensitivity analysis was carried out with a more stringent definition for the control group by excluding a broad range of pain conditions. Results. Total health care costs for patients with CLBP were double those of the matched controls (1074 pound vs. 516; pound P < 0.05). Of the cost difference, 58.8% was accounted for by general practitioner's consultations, 22.3% by referrals to secondary care, and the rest by pain relief medications. The sensitivity analysis revealed an even greater cost difference between the 2 groups (1052 pound vs. 304; pound P < 0.05). Because of the use of a retrospective administrative claims database, this study is subject to selection bias between study cohorts, misidentification of comorbidities, and an inability to confirm adherence to therapy or assess indirect costs and costs of over-the-counter medications. Conclusion. Our findings confirm the substantial economic burden of CLBP, even with direct costs only.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据